Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions

Authors: Giovanni P Burrai, Sulma I Mohammed, Margaret A Miller, Vincenzo Marras, Salvatore Pirino, Maria F Addis, Sergio Uzzau, Elisabetta Antuofermo

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Breast cancer is the most frequently diagnosed cancer in women. Intraepithelial lesions (IELs), such as usual ductal hyperplasia (UH), atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) are risk factors that predict a woman's chance of developing invasive breast cancer. Therefore, a comparative study that establishes an animal model of pre-invasive lesions is needed for the development of preventative measures and effective treatment for both mammary IELs and tumors. The purpose of this study was to characterize the histologic and molecular features of feline mammary IELs and compare them with those in women.

Methods

Formalin-fixed, paraffin-embedded specimens (n = 205) from 203 female cats with clinical mammary disease were retrieved from the archives of the Purdue University Animal Disease Diagnostic Laboratory and Veterinary Teaching Hospital (West Lafayette, IN), and the Department of Pathology and Veterinary Clinic, School of Veterinary Medicine (Sassari, Italy). Histologic sections, stained with hematoxylin and eosin (HE), were evaluated for the presence of IELs in tissue adjacent to excised mammary tumors. Lesions were compared to those of humans. Immunohistochemistry for estrogen receptor (ER-alpha), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2/neu) and Ki-67 was performed in IELs and adjacent tumor tissues.

Results

Intraepithelial lesions were found in 57 of 203 (28%) feline mammary specimens and were categorized as UH (27%), ADH (29%), and DCIS (44%). Most IELs with atypia (ADH and DCIS) were associated with mammary cancer (91%), whereas UH was associated with benign lesions in 53% of cases. Feline IELs were remarkably similar to human IELs. No ER or PR immunoreactivity was detected in intermediate-grade or high-grade DCIS or their associated malignant tumors. HER-2 protein overexpression was found in 27% of IELs.

Conclusion

The remarkable similarity of feline mammary IELs to those of humans, with the tendency to lose hormone receptor expression in atypical IELs, supports the cat as a possible model to study ER- and PR-negative breast lesions.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 58: 71-96. 10.3322/CA.2007.0010.CrossRef
2.
O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002, 8: 314-46.PubMed
3.
Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985, 312 (3): 146-51.CrossRefPubMed
4.
Page DL, Jensen RA, Simpson JF, Dupont WD: Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000, 5: 341-349. 10.1023/A:1009521726605.CrossRefPubMed
5.
Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005, 143: 446-457.CrossRefPubMed
6.
Hansen K, Khanna C: Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer. 2004, 40 (6): 858-80. 10.1016/j.ejca.2003.11.031.CrossRefPubMed
7.
Allred DC, Medina D: The relevance of mouse models to understanding the development and progression of human breast cancer. J Mammary Gland Biol Neoplasia. 2008, 13 (3): 279-88. 10.1007/s10911-008-9093-5.CrossRefPubMed
8.
Porrello A, Cardelli P, Spugnini EP: Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res. 2006, 25 (1): 97-105.PubMed
9.
Weijer K, Head KW, Misdorp W, Hampe JF: Feline malignant mammary tumors. I. Morphology and biology: some comparisons with human and canine mammary. J Natl Cancer Inst. 1972, 49: 1697-704.PubMed
10.
MacEwen EG: Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev. 1990, 9: 125-36. 10.1007/BF00046339.CrossRefPubMed
11.
Misdorp W: Tumors of the mammary gland. Tumors in domestic animals. Edited by: Meuten DJ. 2002, Iowa: Blackwell, 575-606. full_text. 4
12.
Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M: Feline mammary tumours in comparative oncology. Journal of Dairy Research. 2005, 72 (Special): 98-106. 10.1017/S0022029905001263.CrossRefPubMed
13.
Overley B, Shofer FS, Goldschmidt MH, Sherer D, Sorenmo KU: Association between ovariohysterectomy and feline mammary carcinoma. J Vet Intern Med. 2005, 19: 560-563.CrossRefPubMed
14.
Misdorp W, Romijn A, Hart AA: Feline mammary tumors: a case-control study of hormonal factors. Anticancer Res. 1991, 11: 1793-1797.PubMed
15.
Misdorp W: Progestagens and mammary tumours in dogs and cats. Acta Endocrinol. 1991, 125: 27-31.PubMed
16.
Kelsey JL, Gammon MD, John EM: Reproductive factors and breast cancer. Epidemiol Rev. 1993, 15: 36-47.PubMed
17.
McGuire WL, Osborne CK, Clark GM, Knight WA: Steroid hormone receptors and carcinoma of the breast. Am J of Physiol. 1982, 243: 99-102.
18.
Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Wärri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA: Estrogen receptor beta in breast cancer. Endocr Relat Cancer. 2002, 9: 1-13. 10.1677/erc.0.0090001.CrossRefPubMed
19.
Allred DC, Brown P, Medina D: The origins of estrogen receptor positive and negative human breast cancer. Breast Cancer Res. 2004, 6: 240-245. 10.1186/bcr938.CrossRefPubMedPubMedCentral
20.
de las Mulas JM, van Niel M, Millan Y, Blankenstein MA, van Mil F, Misdorp W: Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol. 2000, 18: 111-125. 10.1016/S0739-7240(99)00067-3.CrossRefPubMed
21.
Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001, 411: 355-365. 10.1038/35077225.CrossRefPubMed
22.
Sahin AA: Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol. 2000, 7: 158-166. 10.1097/00125480-200007030-00005.CrossRefPubMed
23.
De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF: Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65: 907-912.PubMed
24.
Ordás J, Millán Y, Dios R, Reymundo C, de las Mulas JM: Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer. 2007, 7: 179-10.1186/1471-2407-7-179.CrossRefPubMedPubMedCentral
25.
Millanta F, Calandrella M, Citi S, Della Santa D, Poli A: Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey an evaluation of its prognostic potential. Vet Pathol. 2005, 42: 30-34. 10.1354/vp.42-1-30.CrossRefPubMed
26.
Rosen PP: Rosen's breast pathology. 2001, Lippincott Williams & Wilkins: Philadelphia, PA, 2
27.
The Consensus Conference Committee: Consensus conference on the classification of ductal carcinoma in situ. Cancer. 1997, 80: 1798-1802. 10.1002/(SICI)1097-0142(19971101)80:9<1798::AID-CNCR15>3.0.CO;2-0.CrossRef
28.
Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R, Page DL: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992, 16: 1133-43. 10.1097/00000478-199212000-00001.CrossRefPubMed
29.
Misdorp W, Else RW, Hellmen E, Limpiscomb TP: Histological classification of the mammary tumors of the dog and the cat. World Health Organization International Histological Classification of Tumors of Domestic Animals. 2nd Series. 1999, Washington, D.C: Armed Force Institute of Pathology, 7:
30.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
31.
Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M: Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol. 1998, 119: 263-275. 10.1016/S0021-9975(98)80049-2.CrossRefPubMed
32.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.CrossRefPubMed
33.
Westermeier R: Sensitive, quantitative and fast modifications for Coomassie blue staining of polyacrilamide gels. Proteomics. 2006, 6: 61-64. 10.1002/pmic.200690121.CrossRefPubMed
34.
Seixas F, Palmeira C, Pires MA, Lopesn C: Mammary invasive micropapillary carcinoma in cats: clinicopathologic features and nuclear DNA content. Vet Pathol. 2007, 44 (6): 842-848. 10.1354/vp.44-6-842.CrossRefPubMed
35.
Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist. 2007, 12: 1276-1287. 10.1634/theoncologist.12-11-1276.CrossRefPubMed
36.
Cardiff RD, Moghanaki D, Jensen RA: Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia. 2000, 5: 421-437. 10.1023/A:1009534129331.CrossRefPubMed
37.
Munson L, Moresco A: Comparative pathology of mammary gland cancers in domestic and wild animals. Breast Dis. 2007, 28: 7-21.CrossRefPubMed
38.
Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993, 71: 1258-1265. 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I.CrossRefPubMed
39.
Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst. 1998, 90: 37-42. 10.1093/jnci/90.1.37.CrossRefPubMed
40.
Millanta F, Calandrella M, Vannozzi I, Poli A: Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec. 2006, 158: 821-824.CrossRefPubMed
41.
de las Mulas JM, Van Niel M, Millán Y, Blankenstein MA, Van Mil F, Misdorp W: Progesterone receptors in normal, dysplastic and tumorous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci. 2002, 72: 153-161. 10.1053/rvsc.2001.0542.CrossRef
42.
Millanta F, Lazzeri G, Mazzei M, Vannozzi I, Poli A: MIB-1 labeling index in feline dysplastic and neoplastic mammary lesions and its relationship with postsurgical prognosis. Vet Pathol. 2002, 39: 120-126. 10.1354/vp.39-1-120.CrossRefPubMed
43.
Dias Pereira P, Carvalheira J, Gärtner F: Cell proliferation in feline normal, hyperplastic and neoplastic mammary tissue - an immunohistochemical study. Vet J. 2004, 168: 180-185. 10.1016/j.tvjl.2003.10.018.CrossRefPubMed
44.
Castagnaro M, De Maria R, Bozzetta E, Ru G, Casalone C, Biolatti B, Caramelli M: Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. Res Vet Sci. 1998, 65: 223-226. 10.1016/S0034-5288(98)90147-3.CrossRefPubMed
45.
Gullick WJ, Srinivasan R: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat. 1998, 52: 43-53. 10.1023/A:1006107016969.CrossRefPubMed
46.
Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R: Assessment of HER2 status in breast cancer: why, when and how?. Eur J Cancer. 2000, 36 (2): 170-176. 10.1016/S0959-8049(99)00264-6.CrossRefPubMed
47.
Antuofermo E, Miller MA, Pirino S, Xie J, Badve S, Mohammed SI: Spontaneous mammary intraepithelial lesions in dogs - a model of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16 (11): 2247-2256. 10.1158/1055-9965.EPI-06-0932.CrossRefPubMed
Metadata
Title
Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions
Authors
Giovanni P Burrai
Sulma I Mohammed
Margaret A Miller
Vincenzo Marras
Salvatore Pirino
Maria F Addis
Sergio Uzzau
Elisabetta Antuofermo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-156

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Adherence to cancer screening guidelines across Canadian provinces: an observational study

Research article

Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity

Technical advance

A new method to detect loss of heterozygosity using cohort heterozygosity comparisons

Research article

hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis

Research article

Prognostic utility of chromosomal instability detected by fluorescence in situ hybridization in fine-needle aspirates from oral squamous cell carcinomas

Research article

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits